By in

Sativa Strategic Update - 8th May 2019

Press Release                                                                                                                      2nd May 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC 

 (“Sativa” or “the Company”)

 Strategic Update 

Reclassification as a trading Company 

Proposed name change 

RSM appointed as Auditor 

 

 Sativa Investments PLC (NEX: SATI), which joined the NEX Exchange Growth Market in March 2018 as the UK’s first medicinal cannabis investment vehicle, is pleased to announce a strategic update ahead of the Company’s announcement of audited results for the year ended 31 December 2018, scheduled for 13 May 2019. 

Strategic Update 

Due to the faster than expected advancement of the UK Medicinal Cannabis regulatory environment, and the evolution in consumer demand for Cannabidiol (CBD) products across Europe, Sativa has amended its strategy to focus more on UK operations, which already include 100% ownership of two UK based businesses, CBD manufacturer, wholesaler and retailer George Botanicals, and PhytoVista Laboratories, an independent testing facility that analyses both the Company’s and third parties’ products and compounds. The Company also has a 60% controlling share in a German subsidiary. 

Sativa has announced the opening of its first Goodbody & Blunt retail wellness centre in early summer. 

In October 2018, Sativa signed an option over a 7.53 acre site in Wiltshire to allow it to evaluate the commercial viability of developing and owning a large-scale UK growing facility. The Company has since concluded that smart-sourcing of the raw material, to which the Company can then add value through advanced extraction, manufacture, testing, distribution and research of medicinal cannabis and CBD products, will provide greater returns to the Company than growing its own supply. The option, which was acquired at a cost of £85,000, will therefore be allowed to lapse on 1 July 2019. 

The Company’s application for a Home Office Research & Development licence to grow medicinal cannabis is proceeding well. This application, if approved, is expected to meet the immediate need to satisfy the Company’s three-year research agreement with King’s College London relating to the impact of cannabinoids on inflammation and respiratory diseases. Subject to the grant of the licence, the Company will grow a limited number of cannabis plant varieties to order at its highly secure test production facility. The Company is planting imminently its second crop of hemp, covered by its low THC growing licence. 

Proposed name change 

As Sativa has substantially fulfilled the investment strategy set out when it joined the NEX Exchange Growth Market, the Company will now be classified as a trading company, rather than an investment vehicle. The Directors believe that this might broaden the appeal of the equity opportunity to additional institutions and family offices, many of which are precluded from investing in fund-type vehicles. 

To reflect this re-classification, the Company intends to change its name to Sativa Group Plc, and a resolution to that effect will be put to shareholders at the forthcoming AGM. 

RSM appointed as Auditor 

In tandem with its expansion plans, the Company has appointed international audit and advisory firm RSM as the Company’s Auditor, and RSM will be reporting on the Company’s results for the year ended 31 December 2018 which are due to be released on Monday 13 May 2019. The audit team is led by Partner Neil Stephenson. 

Commenting on these developments, Chief Executive and Founder Geremy Thomas said: “Sativa delivered on its Listing objectives expeditiously and is now into its next phase of becoming a full-spectrum Group covering the key value-add parts of the medicinal cannabis and CBD industries. 

“The Group has an exciting future and the team is looking forward to achieving future key milestones including the opening of the Bath Goodbody & Blunt store and the planting of the first seeds at our test and growing facility once Home Office approval is granted.” 

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

gm@peterhousecap.com

 

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

SativaInvestments@abchurch-group.com

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634

 

 

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option ona 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Sativa to open first Goodbody & Blunt wellness centre in Bath with lease signed

Press Release                                                                                                                      2nd May 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC 

 (“Sativa” or “the Company”)

Sativa to open first Goodbody & Blunt wellness centre in Bath with lease signed 

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, is to open the first of its Goodbody & Blunt wellness centres in Bath and has leased a 60.67 sq. m (653 sq. ft) retail unit with frontage on to the prime, high footfall, Broad Street and Milson Place City-centre shopping destinations. 

The store will offer a wide range of Cannabidiol (“CBD”) products and will include a café for customers to consume CBD infused coffee, tea and water.  Customers will also be able to buy CBD sport’s energy shots and also specially selected CBD coffee and tea in bean form to take home and enjoy in their own environment. 

The UK is fast-recognising, along with North America and much of Europe, CBD as a valuable alternative medicine and treatment.  Sativa already has a well-established on-line and wholesale brand, George Botanicals, which has developed bespoke white label products for Goodbody & Blunt.  The store will also stock high quality CBD products from around the world.  Every item stocked by the Goodbody & Blunt stores will have passed rigorous industry-leading tests, conducted by Sativa’s own PhytoVista Laboratories which analyses the quality and the levels of the CBD compound contained within products, both for its own sales and also third parties.  That analysis ensures that every stock item achieves full compliance within regulatory limits. 

The Bath store is the first of three pilot stores after which the Company intends to roll-out a national franchise network, because the Directors believe that this is the fastest and least capital-intensive route to a national footprint.  The Company feels a direct consumer relationship is very important in order to support its future franchisees and brand development. 

As announced in January 2019, the Goodbody & Blunt initiative is led by Chris Jones, a recognised retail expert whose experience includes the early deployment of the Phones 4U retail presence. 

In tandem with the launch of the Goodbody & Blunt chain, the Company is working closely with the Food Standards Authority (FSA) as it deliberates how to regulate CBD products, an initiative that Sativa welcomes and is delighted to assist in. 

Geremy Thomas, Chief Executive and founder, said:  “Sativa was first to market as a UK-quoted medical cannabis investment vehicle and continues to lead the way with its seed to consumer strategy.  Goodbody & Blunt’s high-street CBD outlets will break with tradition, delivering high-end wellness centres with fully trained staff to advise on the quality and provenance of products.  

“Key value drivers to Sativa’s business model include brand recognition and distribution, and the Goodbody & Blunt initiative provides both, alongside the Group’s other brands of George Botanicals and PhytoVista laboratories. 

“Sativa is a full-spectrum Group of businesses within the medicinal cannabis and CBD industries, offering in-house validated testing alongside retail, and is progressing well with an R&D Home Office licence application that will facilitate the Company supplying Kings’ College London with medicinal cannabis research product from its secure growing facility.” 

The Bath store is expected to open in early summer 2019. 

The Directors of the Company accept responsibility for the contents of this announcement. 

–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

gm@peterhousecap.com

 

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

SativaInvestments@abchurch-group.com

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634

 

 

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option ona 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Sativa begins cannabinoid research with King’s College London

Press Release                                                                                                                      2nd April 2019

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC 

 (“Sativa” or “the Company”)

Sativa begins cannabinoid research with King’s College London 

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle,has entered into a research agreement with King’s College London (“the College”) to research the impact of cannabinoids on inflammation and respiratory diseases. 

The research will be led by Professor Clive Page OBE PhD Professor of Pharmacology at King’s College London.  Professor Page is a world authority on the pharmacology of inflammation and respiratory disease, having published over 250 scientific papers.  He is a Fellow of the Royal Society of Biology and the British Pharmacological Society, and was awarded an OBE in 2017 for his “Services to Pharmacology.” 

Sativa, which has a medicinal cannabis grower’s licence in process through the Home Office Drugs Licensing and Compliance Unit, will, subject to regulatory consent, supply the university, to order, with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids.  The Company is able to provide this service through a combination of its commercial agreement with investee business Canada-based Veritas Pharma Inc., which specialises in identifying the optimum cultivation of various strains, and Sativa’s own on-site and highly successful testing facility, PhytoVista Laboratories, that has already undertaken over 1,000 forensic tests relating to a wide variety of cannabinoids, and is accredited and recommended by the UK’s Cannabis Trades Association (“CTA”). 

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King’s College London will assist the medical profession, Government and Regulators in their deliberations. 

“As the UK’s first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago,”

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends –

For further information please contact:

Geremy Thomas

Founder & Chief Executive Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser

Guy Miller and Lucy Williams

Peterhouse Capital Limited 

+44 (0) 20 7469 0930

gm@peterhousecap.com

 

Financial PR and IR

Abchurch Communications

Julian Bosdet / Dylan Mark /

Alejandra Campuzano

Abchurch Switchboard

SativaInvestments@abchurch-group.com

Joseph Colliver

Chief Financial Officer

Sativa Investments PLC

+44 (0) 20 7971 1255

enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634

 

 

+44 (0) 20 7469 4630

www.abchurch-group.com

Notes to Editors

Sativa invests in well-placed ventures within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed-to-consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has already made six investments to date, these being Canada-based and dual-listed emerging pharmaceutical company,Veritas Pharma Inc. (“Veritas Pharma” or “Veritas”), CSE-listed Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc. (“RDT”), which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals Ltd (of which Sativa has 100 per cent ownership), PhytoVista Laboratories (of which Sativa also has 100 per cent ownership), a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil, a joint venture withGermany’s Lexamed GmbH, and an option ona 7.53-acre development site in Wiltshire with the potential to build a glasshouse for growing raw cannabis for medicinal and CBD use. 

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency, which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com